AngioDynamics kept at outperform by RBC

RBC Capital Markets analyst Phil Nalbone maintained AngioDynamics Inc. at outperform, speculative risk, and reduced his price target by $3 to $30. The company's fourth-quarter sales were a little better than expected, at $23.6 million, beating the analyst's estimate by roughly $400,000. Earnings per share fell short at $0.19, 1 cent below the RBC's estimate. Management provided initial guidance for 2007 that calls for revenue growth of 28% to $101 million and pro forma EPS of $0.71. Shares of the Queensbury, N.Y.-based medical device company were down $3.02, or 14.60%, at $17.67, on volume of 1,741,512 shares versus the three-month running average of 132,008 shares. (Nasdaq: ANGO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.